Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
From MaRDI portal
Publication:4335592
DOI10.2307/2532851zbMATH Open0925.62458OpenAlexW2316222558WikidataQ45101960 ScholiaQ45101960MaRDI QIDQ4335592FDOQ4335592
Authors: Mark R. Conaway, Gina R. Petroni 
Publication date: 26 April 1999
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2532851
Cited In (14)
- Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
- Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
- Graphical comparison of multivariate nonparametric location tests for restricted alternatives
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
- A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases
- Ethical issues in oncology biostatistics
- A hypothesis test of feasibility for external pilot trials assessing recruitment, follow-up, and adherence rates
- A Bayesian Group Sequential Approach for Multiple Endpoints
- Directed walk designs for dose-response problems with competing failure modes
- Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
- Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- Testing statistical hypotheses on stochastic ordering of discrete distributions
- Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm
This page was built for publication: Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4335592)
